SNWV trades 414.3% below Wall Street's consensus target of $54.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SNWV achieves its forward estimates and maintains a stable P/E multiple of 28.4x. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, SANUWAVE Health, Inc. (SNWV) has a Wall Street consensus price target of $54.00, based on estimates from 2 covering analysts. With the stock currently trading at $10.50, this represents a potential upside of +414.3%. The company has a market capitalization of $90M.
Analyst price targets range from a low of $53.00 to a high of $55.00, representing a 4% spread in expectations. The median target of $54.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SNWV trades at a trailing P/E of 25.6x and forward P/E of 28.4x. Analysts expect EPS to grow -80.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MLSSMilestone Scientific Inc. | $31M | $0.35 | — | — | — | — | — |
XTNTXtant Medical Holdings, Inc. | $58M | $0.42 | — | — | — | — | — |
LNTHLantheus Holdings, Inc. | $6.7B | $102.82 | $108.50 | +5.5% | Buy | 19.2x | 17 |
NVCRNovoCure Limited | $2.0B | $17.32 | $33.00 | +90.5% | Buy | — | 15 |
ANIKAnika Therapeutics, Inc. | $215M | $16.03 | — | — | Buy | — | 6 |
OSUROraSure Technologies, Inc. | $314M | $4.37 | $4.00 | -8.5% | Hold | — | 13 |
CNMDCONMED Corporation | $1.1B | $35.11 | $78.00 | +122.2% | Hold | 8.0x | 21 |
MMSIMerit Medical Systems, Inc. | $4.3B | $71.45 | $94.20 | +31.8% | Buy | 17.6x | 14 |
WSTWest Pharmaceutical Services, Inc. | $25.8B | $357.64 | $339.29 | -5.1% | Buy | 41.5x | 15 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying SNWV stock.
The consensus Wall Street price target for SNWV is $54, representing 414.3% upside from the current price of $10.5. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SNWV has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $54 implies 414.3% upside from current levels.
SNWV trades at a forward P/E of 28.3784x, representing a moderate valuation. With analysts targeting $54 (414.3% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $55 for SNWV, while the most conservative target is $53. The consensus of $54 represents the median expectation. These targets typically reflect 12-month expectations.
SNWV is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SNWV stock forecast based on 2 Wall Street analysts shows a consensus price target of $54, with estimates ranging from $53 (bear case) to $55 (bull case). The median consensus rating is "Buy".
SNWV trades at a forward P/E ratio of 28.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 25.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on SNWV, with a "Buy" consensus rating and $54 price target (414.3% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SNWV analyst price targets range from $53 to $55, a 4% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $54 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.